药捷安康-B(02617)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02617 药捷安康-B

交易中 04-27 13:58:08

58.650

+0.050

+0.09%

最高59.300	最低57.450	成交量45.25万
今开58.600	昨收58.600	日振幅3.16%
总市值236.95亿	流通市值181.23亿	总股本4.04亿
成交额2,635万	换手率0.15%	流通股本3.09亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02617","market":"HK","secType":"STK","nameCN":"药捷安康-B","latestPrice":58.65,"timestamp":1777269386930,"preClose":58.6,"halted":0,"volume":452500,"delay":0,"changeRate":0.0008532423208190641,"floatShares":309000000,"shares":404000000,"eps":-0.8719840137920225,"marketStatus":"交易中","change":0.05,"latestTime":"04-27 13:58:08","open":58.6,"high":59.3,"low":57.45,"amount":26351700,"amplitude":0.03157,"askPrice":58.9,"askSize":2000,"bidPrice":58.65,"bidSize":500,"shortable":3,"etf":0,"ttmEps":-0.8719840137920225,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1777277400000},"marketStatusCode":2,"adr":0,"listingDate":1750608000000,"exchange":"SEHK","adjPreClose":58.6,"openAndCloseTimeList":[[1777253400000,1777262400000],[1777266000000,1777276800000]],"volumeRatio":0.612179,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02617","defaultTab":"news","newsList":[{"id":"1110590242","title":"药捷安康-B：4月21日发行约508.5万股H股，总额约2.90亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1110590242","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1110590242?lang=zh_cn&edition=full","pubTime":"2026-04-21 19:12","pubTimestamp":1776769948,"startTime":"0","endTime":"0","summary":"2026年4月21日，药捷安康(南京)科技股份有限公司（02617）公告披露已通过配售方式发行5,085,000股H股，占发行前已发行股本约1.67%，每股发行价为57.03港元，合计募资约2.90亿港元。发行完成后，公司已发行股本增至308,851,673股。\n据公告，本次发行基于公司于2025年8月4日举行股东周年大会所授出的一般授权进行。公司同时确认，已遵守香港联交所证券上市规则及相关法律法规。公告由公司董事长兼首席执行官吴永谦签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"药捷安康-B：4月21日发行约508.5万股H股，总额约2.90亿港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629033558","title":"药捷安康-B(02617)完成配售合共508.5万股配售股份 净筹约2.82亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2629033558","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629033558?lang=zh_cn&edition=full","pubTime":"2026-04-21 19:05","pubTimestamp":1776769532,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药捷安康-B 发布公告，配售协议所载所有条件均已达成，有关配售事项已于2026年4月21日完成。配售代理已成功以每股配售股份57.03港元的配售价向不少于六名承配人配售合共508.5万股配售股份。508.5万股配售股份相当于紧接完成前现有已发行H股数目的约1.67%及现有已发行股份数目的1.27%，及经配发及发行配售股份扩大后的已发行H股数目的约1.65%及已发行股份数目的约1.26%。配售事项所得款项总额及所得款项净额分别约为2.9亿港元及2.82亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431415.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629777358","title":"药捷安康-B(02617)在2026年AACR展示谱系重塑作为HR+乳腺癌内分泌治疗的耐药机制以及替恩戈替尼的临床前数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2629777358","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629777358?lang=zh_cn&edition=full","pubTime":"2026-04-21 08:04","pubTimestamp":1776729879,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药捷安康-B 公布，公司在2026年美国癌症研究协会年会上以壁报形式披露了谱系可塑性作为HR+乳腺癌内分泌耐药的驱动机制及其临床转化意义。上述发现支持双靶点FGFR-JAK阻断作为克服谱系可塑性驱动的内分泌耐药的有效策略。目前，替恩戈替尼联合内分泌治疗晚期HR+乳腺癌的II期临床试验正在进行中。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1431040.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02617","BK4203","BK1161","BK4225","HR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628781605","title":"格隆汇沽空预警榜 | 4月16日","url":"https://stock-news.laohu8.com/highlight/detail?id=2628781605","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628781605?lang=zh_cn&edition=full","pubTime":"2026-04-18 02:15","pubTimestamp":1776449700,"startTime":"0","endTime":"0","summary":"格隆汇勾股大数据显示，上一交易日大市沽空比例为20.22%，过去两个月大市日均沽空比例为20.98%。其中，价值黄金-R、GX创新蓝筹十强、华夏沪深三百-U沽空比率排名前三位，分别为100.00%、100.00%、100.00%。盈富基金、南方恒生科技、恒生中国企业的沽空金额排名前三位，分别为55.27亿、37.99亿、35.30亿。维升药业-B、应星控股、碧桂园的偏离值排名前三位，分别为7.83、4.67、4.28。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2026/04/18021556797242.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["SGCmain","09988","SGUmain","09888","GCmain","01330","89888","BIDU","TCHmain","002594","80020","81211","NUGT","01810","89988","MIUmain","82318","HXXD.SI","02007","HBBD.SI","MPNGY","HYDD.SI","01426","03750","518880","02800","METmain","03133","02828","159934","GLD","MCHmain","03033","81810","03690","02617","03453","BYDDY","XIACY","HMTD.SI","00373","BABA","09188","01211","HTCD.SI","03422","03185","00700","ALBmain","01440"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628227042","title":"药捷安康-B(02617)：替恩戈替尼单药治疗晚期胆管癌患者确证性III期临床完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2628227042","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2628227042?lang=zh_cn&edition=full","pubTime":"2026-04-17 18:41","pubTimestamp":1776422489,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药捷安康-B(02617)公布，公司核心产品替恩戈替尼(Tinengotinib, TT-00420)单药治疗晚期胆管癌患者的确证性III期临床研究，于近日完成首例患者给药。本试验为在中国开展的一项评价替恩戈替尼对比化疗用于既往经一线系统性治疗后复发或进展的、携带FGFR2融合╱重排或突变的、手术不可切除的晚期或转移性肝内胆管癌患者的疗效与安全性的随机对照、开放、多中心III期临床研究。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1430049.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02617","BK4134","III","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627209684","title":"药捷安康-B(02617)拟折让约18.00%发行508.5万股配售股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2627209684","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2627209684?lang=zh_cn&edition=full","pubTime":"2026-04-15 07:02","pubTimestamp":1776207769,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药捷安康-B 发布公告，于2026年4月14日，本公司与配售代理订立配售协议，配售代理有条件同意作为本公司的配售代理，按尽力基准促使承配人按每股配售股份57.03港元的配售价购买508.5万股配售股份。每股配售股份57.03港元的配售价较股份于2026年4月14日在联交所所报的收市价每股H股69.55港元折让约18.00%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1428570.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625953833","title":"药捷安康-B(02617)建议采纳H股股份奖励计划","url":"https://stock-news.laohu8.com/highlight/detail?id=2625953833","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625953833?lang=zh_cn&edition=full","pubTime":"2026-04-07 20:19","pubTimestamp":1775564350,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药捷安康-B(02617)发布公告，董事会已于2026年4月7日举行的董事会会议上议决建议采纳H股股份奖励计划。奖励的授予将透过库存股或本公司发行的新H股(统称“新股”)或现有H股满足。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1425569.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177369602","title":"药捷安康-B3月无新增发行或股份变动","url":"https://stock-news.laohu8.com/highlight/detail?id=1177369602","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177369602?lang=zh_cn&edition=full","pubTime":"2026-04-02 15:46","pubTimestamp":1775116002,"startTime":"0","endTime":"0","summary":"药捷安康(南京)科技股份有限公司于2026年4月2日披露的月报表显示，截至2026年3月31日，公司法定注册股本总额为398,997,633股，与上月底持平。其中，包括303,766,673股H股和95,230,960股非上市股份，两者均无变动。\n报告期内未有新增发行、购回或注销股份，亦不存在任何库存股变动；公司无期权、权证或可换股票据相关业务变动。公司确认其所有交易均遵守香港联合交易所《上市规则》及相关法律规定。\n本次公告由联席公司秘书黄荻签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623586909","title":"药捷安康-B(02617)建议委任冯维波为独立非执行董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2623586909","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623586909?lang=zh_cn&edition=full","pubTime":"2026-03-31 19:54","pubTimestamp":1774958093,"startTime":"0","endTime":"0","summary":"因个人工作安排，郑哲兰女士已决定辞任独立非执行董事、董事会薪酬与考核委员会主席以及董事会审计委员会及提名委员会成员。经提名委员会的资格审查后，于2026年3月31日召开的董事会会议上，公司审议及批准建议委任冯维波先生为独立非执行董事并同意提名冯维波先生为独立非执行董事候选人，同时兼任薪酬与考核委员会主席以及审计委员会及提名委员会成员，其任期自公司于应届股东周年大会上批准之日起至3年后止。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423206.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2623226588","title":"药捷安康-B(02617)发布2025年度业绩，净亏损2.96亿元，同比扩大7.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2623226588","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2623226588?lang=zh_cn&edition=full","pubTime":"2026-03-31 18:46","pubTimestamp":1774953986,"startTime":"0","endTime":"0","summary":"智通财经APP讯，药捷安康-B 发布截至2025年12月31日止年度业绩，其他收入及收益同比下降48.6%至2025年度的920万元，该等减少主要是由于银行存款利息及理财收入减少500万元，政府补助较同期减少370万元。净亏损2.96亿元，同比扩大7.8%;每股基本亏损0.76元。研发成本同比上升1%至2025年度的2.468亿元，保持相对稳定，略有增长，主要是公司聚焦核心产品与关键技术研发，优化资源配置，持续提升产品竞争力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1423100.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620416872","title":"药捷安康－Ｂ(02617.HK)拟3月31日举行董事会会议审批年度业绩","url":"https://stock-news.laohu8.com/highlight/detail?id=2620416872","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620416872?lang=zh_cn&edition=full","pubTime":"2026-03-19 18:37","pubTimestamp":1773916624,"startTime":"0","endTime":"0","summary":"格隆汇3月19日丨药捷安康－Ｂ(02617.HK)宣布，谨定于2026年3月31日(星期二)举行董事会会议，藉以(其中包括)考虑及批准公司及其附属公司截至2025年12月31日止年度的年度业绩公告及其发布、宣派末期股息(如有)以及处理任何其他事项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260319/32081894.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620294150","title":"港股公告掘金 | 腾讯控股发布全年业绩，股东应占盈利2248.42亿元 同比增加16% 末期股息每股5.3港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2620294150","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620294150?lang=zh_cn&edition=full","pubTime":"2026-03-19 09:10","pubTimestamp":1773882658,"startTime":"0","endTime":"0","summary":"重大事项：圣贝拉集团(02508)与L Catterton达成战略合作 共同打造跨领域的高端母婴与生活方式生态微创脑科学(02172)：APOLLO Dream雷帕霉素靶向洗脱支架系统荣获FDA突破性医疗器械认定药捷安康-B(02617)：替恩戈替尼联合氟维司群用于经治失败的HR+/HER2-复发或转移性乳腺癌患者的II期临床完成首例患者给药开拓药业-B(09939)：KX-826酊1.0%治疗中","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415726.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1316542783.SGD","00700","LU0348723411.USD","TCHmain","LU1196710864.SGD","LU1251922891.USD","LU0572944931.SGD","LU0501845795.SGD","LU0328353924.USD","LU0414403682.SGD","LU1366334578.USD","LU1917777945.USD","BK1531","02172","LU0054237671.USD","LU2051468812.USD","LU1655091459.SGD","LU1048588211.SGD","SG9999015952.SGD","LU1226287529.USD","LU0633140727.USD","IE00B031J352.USD","LU0320764599.SGD","LU0072913022.USD","LU0516422952.EUR","LU0611395673.USD","HK0000306685.HKD","02617","LU0918141705.HKD","LU2097828805.USD","LU1568876335.HKD","LU2498475776.HKD","LU1152091168.USD","LU0048580855.USD","SG9999001689.USD","SG9999015945.SGD","LU0648948544.HKD","LU0572940350.SGD","HTCD.SI","LU0791590937.USD","02508","IE0008368411.USD","LU0348783233.USD","LU0048388663.USD","LU0577902454.USD","LU1725190679.HKD","VXUS","LU0210533765.USD","LU1188198961.HKD","VIG"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2620096232","title":"药捷安康-B(02617)：替恩戈替尼联合氟维司群用于经治失败的HR+/HER2-复发或转移性乳腺癌患者的II期临床完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2620096232","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620096232?lang=zh_cn&edition=full","pubTime":"2026-03-18 18:54","pubTimestamp":1773831280,"startTime":"0","endTime":"0","summary":"本试验为在中国开展的一项评价替恩戈替尼联合氟维司群注射液用于经治失败的HR+╱HER2-的复发或转移性乳腺癌患者的安全性、疗效及药代动力学的开放、多中心、II期临床研究。替恩戈替尼早期临床研究结果表明，其单药在经多种治疗的HR+╱HER2 乳腺癌患者中展现出令人鼓舞的临床效果，支持其与内分泌治疗联用的进一步研发。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415519.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02617","BK4203","BK1161","BK4225","HR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1186668475","title":"一周港股牛熊榜 | 健康160 正式获纳入港股通名单吸引北水参与，一周升逾94%；迅策、中国旭阳集团升近50%强势爆发；联邦制药因盈利预警跌近20%","url":"https://stock-news.laohu8.com/highlight/detail?id=1186668475","media":"老虎资讯综合","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1186668475?lang=zh_cn&edition=full","pubTime":"2026-03-13 16:45","pubTimestamp":1773391539,"startTime":"0","endTime":"0","summary":"此外，公司被调入港股通后吸引北水参与，市场买盘强劲，连续上涨。2025年7月推出的IAP ROAS优化策略成功切入中重度游戏市场，曝光占比从5.54%迅速提升至18.24%。核心业务中间体及原料药因市场价格下跌，导致分部溢利大幅下降。","market":"hk","thumbnail":"https://community-static.tradeup.com/news/549ed9c19f16d97443cb9ffadc6a6514","type":0,"news_type":0,"thumbnails":["https://community-static.tradeup.com/news/549ed9c19f16d97443cb9ffadc6a6514"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02661","02656","01860","01384","02617","03317","01907","02665","03933","02889"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2619685281","title":"每日卖空追踪 | 药捷安康-B 03月12日卖空量成交9000股，卖空比例为0.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2619685281","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619685281?lang=zh_cn&edition=full","pubTime":"2026-03-12 16:30","pubTimestamp":1773304233,"startTime":"0","endTime":"0","summary":"药捷安康-B北京时间03月12日，跌1.76%，卖空量成交9000股，较上一交易日减少28%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312163443a6ba51f6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312163443a6ba51f6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619277168","title":"药捷安康-B03月12日遭主力抛售500.4万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2619277168","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2619277168?lang=zh_cn&edition=full","pubTime":"2026-03-12 16:15","pubTimestamp":1773303338,"startTime":"0","endTime":"0","summary":"03月12日, 药捷安康-B股价跌1.76%，报收75.40元，成交金额1.6亿元，换手率0.68%，振幅6.84%，量比0.17。药捷安康-B今日主力资金净流出500.4万元，上一交易日主力净流出595.5万元。该股近5个交易日上涨17.39%，主力资金累计净流入7018.9万元，其中2个交易日为股价下跌时净流入；近20日主力资金累计净流入8090.8万元，其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312161810a6ba426a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260312161810a6ba426a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","02617"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618092497","title":"药捷安康-B03月11日主力净流出595.5万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2618092497","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618092497?lang=zh_cn&edition=full","pubTime":"2026-03-11 16:15","pubTimestamp":1773216928,"startTime":"0","endTime":"0","summary":"03月11日, 药捷安康-B股价跌3.82%，报收76.75元，成交金额3.3亿元，换手率1.37%，振幅8.15%，量比0.37。药捷安康-B今日主力资金净流出595.5万元，上一交易日主力净流入583.9万元。该股近5个交易日上涨31.23%，主力资金累计净流入7949.6万元，其中2个交易日为股价下跌时净流入；近20日主力资金累计净流入8591.3万元，其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311161656a6b78699&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260311161656a6b78699&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618647764","title":"药捷安康-B(02617)获纳入恒生指数系列成份股","url":"https://stock-news.laohu8.com/highlight/detail?id=2618647764","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618647764?lang=zh_cn&edition=full","pubTime":"2026-03-09 18:43","pubTimestamp":1773053002,"startTime":"0","endTime":"0","summary":"同时，本公司已从恒生综合小型股指数中剔除，自2026年3月9日起生效。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1411714.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["MCHmain","BK1161","HHImain","02617","513600","02833"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2618672771","title":"每日卖空追踪 | 药捷安康-B 03月09日卖空量成交3.05万股，卖空比例为0.25%","url":"https://stock-news.laohu8.com/highlight/detail?id=2618672771","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2618672771?lang=zh_cn&edition=full","pubTime":"2026-03-09 16:30","pubTimestamp":1773045033,"startTime":"0","endTime":"0","summary":"药捷安康-B北京时间03月09日，跌7.01%，卖空量成交3.05万股，较上一交易日减少74.79%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309163448a45ae8a7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260309163448a45ae8a7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617652549","title":"药捷安康-B03月06日获主力加仓7031.0万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2617652549","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617652549?lang=zh_cn&edition=full","pubTime":"2026-03-06 16:15","pubTimestamp":1772784920,"startTime":"0","endTime":"0","summary":"03月06日, 药捷安康-B股价涨43.53%，报收92.00元，成交金额26.1亿元，换手率10.25%，振幅47.27%，量比13.74。药捷安康-B今日主力资金净流入7031.0万元，连续4日净流入，上一交易日主力净流入430.3万元。该股近5个交易日上涨33.53%，主力资金累计净流入7833.1万元，其中2个交易日为股价下跌时净流入；近20日主力资金累计净流入8385.3万元，其中净流入天数为9日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306161603a6aa29bc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260306161603a6aa29bc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02617","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.transtherabio.com","stockEarnings":[{"period":"1week","weight":-0.1532},{"period":"1month","weight":-0.1489},{"period":"3month","weight":-0.2982},{"period":"6month","weight":-0.6932},{"period":"1year","weight":3.4563},{"period":"ytd","weight":-0.49}],"compareEarnings":[{"period":"1week","weight":-0.007},{"period":"1month","weight":0.0253},{"period":"3month","weight":-0.0288},{"period":"6month","weight":-0.007},{"period":"1year","weight":0.1857},{"period":"ytd","weight":0.0136}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"药捷安康（南京）科技股份有限公司是一家从事生物制药的中国公司，主要专注于发现及开发肿瘤、炎症及心脏代谢疾病小分子创新疗法。该公司的核心产品Tinengotinib是一种处于注册临床阶段的内部发现和开发的MTK抑制剂，适用于某些复发或难治的耐药实体瘤。该公司的肿瘤产品线包括TT-00973（针对 AXL）、TT-01488（用于血液系统恶性肿瘤）、TT-01688（用于炎症性疾病）和 TT-00920（用于慢性心力衰竭）。这些产品能够对多种癌症类型（包括前列腺癌、肝癌、乳腺癌和BTC）产生疗效。它还可用于治疗肝细胞癌、乳腺癌、胆道癌和Pan-FGFR实体瘤。","exchange":"SEHK","name":"药捷安康-B","nameEN":"TRANSTHERA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"药捷安康-B(02617)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供药捷安康-B(02617)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"药捷安康-B,02617,药捷安康-B股票,药捷安康-B股票老虎,药捷安康-B股票老虎国际,药捷安康-B行情,药捷安康-B股票行情,药捷安康-B股价,药捷安康-B股市,药捷安康-B股票价格,药捷安康-B股票交易,药捷安康-B股票购买,药捷安康-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"药捷安康-B(02617)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供药捷安康-B(02617)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}